Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

experience delays in the conduct or completion of the PROPEL trial, whether caused by competition, adverse events, patient enrollment rates, regulatory issues or other factors; that clinical trials may not demonstrate that PDX is both safe and effective for the treatment of patients with PTCL or any other type of cancer; that data from preclinical studies and clinical trials may not be indicative of future clinical trial results; that the safety and/or efficacy results of the PROPEL trial may not support an application for marketing approval in the United States or any other country; that an application for marketing approval may not be accepted for priority review or at all by the FDA or any other regulatory authority; and that the Company may lack the financial resources and access to capital to fund future clinical trials for PDX or any of its other product candidates. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2006 and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this presentation, except as required by law.

Note: The Allos logo is a trademark of Allos Therapeutics, Inc.


'/>"/>
SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015  China Nepstar Chain Drugstore ... leading retail drugstore chain in China ... today announced the resignation of Mr. Fuxiang Zhang ... reasons, effective immediately. Ms. Rebecca Yingnan Zhang ... Company,s board of directors, effective immediately. Meanwhile, Ms. Zhang ...
(Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
(Date:5/21/2015)... , 21. Mai 2015 /PRNewswire/ ... DPRX ), ein Unternehmen für Arzneimittel ... die Entwicklung und Vermarktung von Locilex® ... kündigte heute eine wissenschaftliche Posterpräsentation an, ... des Unternehmens vorstellt, OneStep-1 und OneStep-2, ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... THE OHIO STATE UNIVERSITY ... CENTER JOINS PHASE III TRIAL FOR METASTATIC MELANOMA ... (Nasdaq: DCTH ) announced today that The Ohio ... Research Institute has joined Delcath,s Phase III clinical trial for the treatment ...
... online this week in the Journal of Clinical ... selective estrogen receptor modulator (SERM) being developed by Eli ... increased lumbar spine and total hip bone mineral density ... mass, versus placebo.In addition, arzoxifene, dosed at 20 mg/day, ...
Cached Medicine Technology:Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM) 2Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM) 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 2Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 3Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density 4
(Date:5/22/2015)... 22, 2015 Pioneer Millworks, the largest ... forefront of designing with reclaimed wood, introducing their latest ... Angeles, California. Their newest offerings, Vat 35, Reclaimed ... and color to America's largest design event. , “Designers, ... each show, anxious to see and feel the variety ...
(Date:5/22/2015)... 2015 River Valley Health Partners (RVHP) ... health system’s Chief Financial Officer (CFO), will be leaving ... as the company CFO since 2011. , The Board ... the health system as CFO. Wesley will oversee the ... the Board of Trustees conducts a formal search for ...
(Date:5/22/2015)... Pa. (PRWEB) May 22, 2015 Omar ... been selected to participate in the 2015 Congress of ... is described as a gathering of “America’s highest achieving ... new areas of healthcare, set new goals and learn ... include a live surgery, during which we can ask ...
(Date:5/22/2015)... “It’s like learning an new ... Vice President of Clinical Operations/Education and Training at ... impacts how care is coded and reimbursed.” , ... care reimbursement, operations and compliance consulting, as well ... launches a new series of day-long seminars on ...
(Date:5/22/2015)... May 22, 2015 Coordinating care ... difficult process. Historically providers have not been reimbursed ... Starting in 2015, Medicare has paved the way ... Thanks to the launch of Oculus Health ... health systems using the platform will now be ...
Breaking Medicine News(10 mins):Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 2Health News:Harmony Healthcare International Takes the Lead in Launching ICD-10 Coding Transition in Post-Acute Care 3Health News:Oculus Health Care Coordination Platform Officially Launched 2Health News:Oculus Health Care Coordination Platform Officially Launched 3Health News:Oculus Health Care Coordination Platform Officially Launched 4
... (NYSE: LNC ) today announced the introduction of ... disability (LTD) insurance product. Lincoln already offers one of the ... the addition of this optional benefit -- employers now have ... cost concerns as they try to return to work. (Logo: ...
... bacteria that threaten those with COPD, study says , , ... smoking help cause chronic obstructive pulmonary disease (COPD), it ... can worsen the disease, Canadian researchers report. , The ... how smokers with COPD are treated, the experts said. ...
... ETS EXPOSURE , Environmental tobacco smoke (ETS) exposure ... However, a new study shows that reducing exposure ... Alabama researchers followed 240 children with asthma who ... therapy. No smoking cessation counseling or ETS exposure ...
... RAC Credential Focuses on General Scope of Regulatory ... The Regulatory Affairs Professionals Society (RAPS) has ... RAC General Scope (GS). The RAC (GS) credential ... practice of regulatory professionals in the healthcare product ...
... DETROIT, April 7 The Detroit Wayne County ... enrollment service that will expedite the screening and ... called HelpEngen(TM), was developed by TriHealix, a health ... enables health care providers to connect uninsured patients ...
... http://www.HealthGuru.com ) was the fastest growing health site on the web over ... of the few health sites with more video views than unique visitors ... ... 7, 2009 -- According to the comScore, Inc. February rankings, Health Guru ...
Cached Medicine News:Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 2Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 3Health News:Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies 4Health News:Smoking Ups Infection Risk for Lung Disease Patients 2Health News:Journal Chest: April news briefs 2Health News:RAPS Offers New International Regulatory Affairs Certification - RAC (GS) 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 2Health News:Health Authority Offers Expedient, Web-Based Medicaid Enrollment Service 3Health News:Web's Fastest Growing Health Site is a Video Site 2Health News:Web's Fastest Growing Health Site is a Video Site 3
... pulsed radiofrequncy current, the Valleylab ... heats and ablates large volumes ... minimal time., RF alblation procedures ... surgery, percutaneously, or laparoscopically, depending ...
... is a biologically based adhesive supplied ... system consisting of a liquid substrate ... of internal bleeding. When ... on to a prepared wound and ...
... (Human) achieves a secure clot, targeted to ... for hemostasis is needed, when control of ... ligature, and cautery, is ineffective or impractical., ... formulation of human Biologically Active Component (BAC) ...
... BD Cell-Tak™ Cell and Tissue Adhesive ... from Mytilus edulis (marine mussel). These proteins ... secreted by the mussel to anchor itself ... BD Cell-Tak Cell and Tissue Adhesive is ...
Medicine Products: